WHY IT MATTERS: Veterans currently using cannabis or pursuing psychedelic therapy outside the VA system risk losing continuity of care, benefits eligibility concerns, and lack of clinical supervision that a formal federal program would provide. CLINICAL OVERVIEW: Veterans organizations are pressing Congress to broaden access to both cannabis and psychedelic-assisted therapies through the VA system as a response to the persistently high suicide rate among veterans. The push reflects growing clinical evidence that current pharmacological and psychological treatment options are failing a significant portion of this population, particularly those with treatment-resistant PTSD and co-occurring substance use disorders.
Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
WHY IT MATTERS: Patients managing anxiety who are curious about cannabis now have additional research supporting CBD-dominant products as a potentially effective option worth discussing with a knowledgeable clinician before making any changes to current treatment. CLINICAL OVERVIEW: CBD-dominant cannabis products are gaining clinical attention as a potential option for anxiety management, with research suggesting meaningful symptom relief in patients who use formulations where cannabidiol predominates over THC. The anxiolytic properties of CBD are thought to involve serotonergic signaling and modulation of the endocannabinoid system, particularly at CB1 receptors and 5-HT1A receptors, which distinguishes its mechanism from both benzodiazepines and SSRIs.
Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. CBDAnxietyResearchMental Health Why This Matters Clinicians treating anxiety disorders need to understand that CBD-dominant cannabis...
The Wait is Over: Medical Cannabis set to roll out in April | WHNT.com
WHY IT MATTERS: Alabama patients with qualifying conditions will soon have legal, regulated access to medical cannabis through licensed dispensaries, potentially replacing unsafe or illegal sources they may have been relying on. CLINICAL OVERVIEW: Alabama is preparing to launch its long-delayed medical cannabis program, marking a significant shift for a state that has historically maintained some of the strictest drug policies in the country. The program will allow qualifying patients with conditions such as chronic pain, PTSD, anxiety, and terminal illness to access cannabis through licensed dispensaries under physician supervision.
The Wait is Over: Medical Cannabis set to roll out in April | WHNT.com
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryPainAnxiety Clinical Summary Alabama's medical cannabis program is set to launch in April after a...
Study Links Rising Cannabis Use to Poor Mental Health – HealthDay
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthResearchAnxietySafety Why This Matters Clinicians should understand this association when screening patients for cannabis...
Pipeline Progress Drives Investor Focus at Agentix – Ad-hoc-news.de
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchPainAnxietyNeurology Why This Matters Agentix's advancement of endocannabinoid-targeting drug candidates represents potential new therapeutic options...
Patient Protect launches to tackle discrimination against UK medical cannabis patients
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyMental HealthAnxietySafety Why This Matters Medical cannabis patients in the UK face practical barriers to...
Pipeline Progress Drives Investor Focus at Agentix – Ad-hoc-news.de
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchNeurologyPainAnxiety Why This Matters As Agentix advances endocannabinoid-targeting drug candidates through clinical development, clinicians should...
Patient Protect launches to tackle discrimination against UK medical cannabis patients
WHY IT MATTERS: If you are a UK medical cannabis patient, dedicated legal support services are now available to help you challenge discrimination in employment, housing, and policing situations that may arise from your prescription. CLINICAL OVERVIEW: Medical cannabis patients in the United Kingdom continue to face real-world consequences that extend well beyond their clinical care, including discrimination in housing decisions, workplace policies, law enforcement encounters, and driving eligibility assessments. These challenges arise because legal frameworks and institutional policies have not kept pace with the formal recognition of medical cannabis as a legitimate prescribed treatment.